The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination
Open accessAbstract
Cases of apparent secondary immune thrombocytopenia (ITP) after SARS-CoV-2 vaccination with both the Pfizer and Moderna versions have been reported and reached public attention. Public alarm was heightened following the death of the first identified patient from an intracranial hemorrhage, which was reported on the Internet, then in USA Today1 and then in The New York Times.2 Described below, we have collected a series of cases of very low platelet counts occurring within 2 weeks of vaccination in order to enhance our understanding of the possible relationship, if any, between SARS-CoV-2 vaccination and development of ITP with implications for surveillance and management. Twenty case reports of patients with thrombocytopenia following vaccination, 17 without pre-existing thrombocytopenia and 14 with reported bleeding symptoms prior to hospitalization were identified upon review of data available from the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), agencies of the U.S. Department of Health and Human Services (HHS) Vaccine Adverse Events Reporting System (VAERS), published reports,3, 4 and via direct communication with patients and treating providers. These cases were investigated as suspicious for new onset, post-vaccination secondary ITP; we could not exclude exacerbation of clinically undetected ITP. Search terms relating to "decreased platelet count", "immune thrombocytopenia", "hemorrhage", "petechiae", and "contusion" were utilized to identify cases reported in VAERS. The reports describing 19 of 20 patients included age (range 22–73 years old; median 41 years) and gender (11 females and 8 males). Nine received the Pfizer vaccine and 11 received the Moderna vaccine. All 20 patients were hospitalized and most patients presented with petechiae, bruising or mucosal bleeding (gingival, vaginal, epistaxis) with onset of symptoms between 1–23 days (median 5 days) post vaccination. Platelet counts at presentation were available for all 20 cases with the majority being at or below 10 × 109/L (range 1–36 × 109/L; median 2 × 109/L). One patient had known ITP in remission; another had mild–moderate thrombocytopenia in 2019 with note of positive anti-platelet antibodies, a third had previous mild thrombocytopenia (145 × 109/L) while a fourth had inherited thrombocytopenia with baseline platelet counts of 40–60 × 109/L. Three other patients had known autoimmune conditions including hypothyroidism, Crohns disease, or positive tests for anti-thyroglobulin antibodies. Treatment for suspected ITP was described in 15 of the cases, including corticosteroids n = 14, intravenous immune globulin (IVIG) n = 12, platelet transfusions n = 8, rituximab n = 2, romiplostim = 1, vincristine = 1, and aminocaproic acid (Amicar) n = 1; combination therapy was used in most patients. Initial outcomes were reported in 16 cases. An improvement in the platelet count was described in patients treated with platelet transfusion alone (n = 1), corticosteroids alone (n = 1), corticosteroids + platelet transfusion (n = 3), corticosteroids + IVIG (n = 3), corticosteroids + IVIG + platelet transfusion (n = 5), corticosteroids +IVIG + rituximab + vincristine + romiplostim (n = 1). The index patient passed away after a cerebral hemorrhage, as mentioned, notwithstanding having received emergent treatment with IVIG, steroids, rituximab and platelet transfusions. Another patient had no improvement in platelet counts after 3 days, but treatment details are not specified. Five additional patients with "thrombocytopenia" or "immune thrombocytopenia" post vaccination were identified in VAERS (last accessed 2/5/21), but either available information is insufficient for inclusion or the clinical scenarios suggest alternative processes contributing to thrombocytopenia. One 59 year-old man was identified with "thrombocytopenia" at an unspecified time after receiving the Pfizer vaccine without additional details regarding platelet count, clinical course, or treatment. A 44 year-old woman was hospitalized for nausea, vomiting and chest pain on the day that she received the Pfizer vaccine. Her laboratory values included a platelet count of 85 × 109/L and a peak troponin level of 4 ng/mL (normal < = 0.04 ng/mL). The patient was diagnosed with myocarditis but did not require treatment for thrombocytopenia. Her platelets were 61 × 109/L on discharge, but subsequent platelet counts were not reported. The third is a patient without age or gender reported who was found to have thrombocytopenia, neutropenia and a pulmonary embolism at an unspecified time following the Pfizer vaccine. This patient was hospitalized and passed away; no additional details were available. A fourth patient, a 37-year-old man, had "thrombocytopenia requiring hospitalization, meds and platelet infusion" 4 days following the Moderna vaccine with no details regarding presenting symptoms, platelet count, treatment or outcome. The last patient is an 80 y
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Cooper, N., Stasi, R., Cunningham‐Rundles, S., Feuerstein, M. A., Leonard, J. P., Amadori, S., & Bussel, J. B. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04889.x · Cited by 336
Self-citationImmune Thrombocytopenia Secondary to COVID-19: a Systematic Review
Bhattacharjee, S., & Banerjee, M. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00521-8 · Cited by 287
Safety of antisense oligonucleotide and siRNA-based therapeutics
Chi, X., Gatti, P., & Papoian, T. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.013 · Cited by 280
Antibody-induced procoagulant platelets in severe COVID-19 infection
Althaus, K., Marini, I., Zlamal, J., Pelzl, L., Singh, A., Häberle, H., Mehrländer, M., Hammer, S., Schulze, H., Bitzer, M., et al. (2021) · Blood · doi:10.1182/blood.2020008762 · Cited by 214
Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children
France, E. K., Glanz, J., Xu, S., Hambidge, S., Yamasaki, K., Black, S. B., Marcy, M., Mullooly, J. P., Jackson, L. A., Nordin, J., et al. (2008) · PEDIATRICS · doi:10.1542/peds.2007-1578 · Cited by 165 · cited 1×
“It is estimated that approximately 1:40 000 children develop secondary ITP after receiving measlesmumps-rubella (MMR) vaccine.(7) Well-documented cases of acquired immune thrombocytopenia have been reported after varicella and other vaccinations as well, including one described in this issue of the American Journal of…”
BackgroundToxicology of antisense therapeutics
Jason, T. L. H., Koropatnick, J. D., & Berg, R. W. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.04.017 · Cited by 161
Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases
Perricone, C., Ceccarelli, F., Nesher, G., Borella, E., Odeh, Q., Conti, F., Shoenfeld, Y., & Valesini, G. (2014) · Immunologic Research · doi:10.1007/s12026-014-8597-x · Cited by 146
The Risk of Immune Thrombocytopenic Purpura After Vaccination in Children and Adolescents
O’Leary, S. T., Glanz, J. M., McClure, D. L., Akhtar, A. Z., Daley, M. F., Nakasato, C. C., Baxter, R. P., Davis, R. L., Izurieta, H. S., Lieu, T. A., et al. (2012) · PEDIATRICS · doi:10.1542/peds.2011-1111 · Cited by 117
Cited by
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
Falsey, A. R., Sobieszczyk, M. E., Hirsch, I., Sproule, S., Robb, M. L., Corey, L., Neuzil, K. M., Hahn, W., Hunt, J., Mulligan, M. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105290 · Cited by 670
COVID-19 vaccine development: milestones, lessons and prospects
Li, M., Wang, H., Tian, L., Pang, Z., Yang, Q., Huang, T., Fan, J., Song, L., Tong, Y., & Fan, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00996-y · Cited by 434
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection
Patone, M., Handunnetthi, L., Saatci, D., Pan, J., Katikireddi, S. V., Razvi, S., Hunt, D., Mei, X. W., Dixon, S., Zaccardi, F., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01556-7 · Cited by 394
Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination
Beatty, A. L., Peyser, N. D., Butcher, X. E., Cocohoba, J. M., Lin, F., Olgin, J. E., Pletcher, M. J., & Marcus, G. M. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.40364 · Cited by 396
Bril, F., Al Diffalha, S., Dean, M., & Fettig, D. M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.04.003 · Cited by 192
Metadata
- Authors
- Lee, E., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M. D., Semple, J. W., Arnold, D. M., Godeau, B., Lambert, M. P., & Bussel, J. B.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2021-03-09
- Volume
- 96
- Issue
- 5
- Pages
- 534-537
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W3131011903
- Cited by
- 388
- References
- 16
- FWCI
- 49.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination. https://app.cochat.ai/papers/10.1002/ajh.26132
- The paper
- Lee, E., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M. D., Semple, J. W., Arnold, D. M., Godeau, B., Lambert, M. P., & Bussel, J. B. (2021). Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination. American Journal of Hematology. https://doi.org/10.1002/ajh.26132
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.